Identification of new potent GPR119 agonists by combining virtual screening and combinatorial chemistry

Journal of Medicinal Chemistry

Volumn 55, Issue 24, 2012, Pages 11031-11041

  Wellenzohn, Bernd ^a   Lessel, Uta ^a   Beller, Andreas ^a   Isambert, Timo ^a   Hoenke, Christoph ^a   Nosse, Bernd ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 OXA 2,8 DIAZA SPIRO[4.5]DEC 2 ENE 3 CARBOXYLIC ACID(2,5 DIFLUORO 4 METHYLSULFANYLPHENYL)AMIDE; 1 OXA 2,8 DIAZA SPIRO[4.5]DEC 2 ENE 3 CARBOXYLIC ACID(4 CYANO 2,5 DIFLUOROPHENYL)AMIDE; 2,5 DIFLUORO 4 METHYLSULFANYLPHENYLAMINE; 3 (4 CYANO 2,5 DIFLUOROPHENYLCARBAMOYL) 1 OXA 2,8 DIAZASPIRO[4.5]DEC 2 ENE 8 CARBOXYLIC ACID TERT BUTYL ESTER; 8 (3 PHENYL[1,2,4]OXADIAZOL 5 YL) 1 OXA 2,8 DIAZA SPIRO[4.5]DEC 2 ENE 3 CARBOXYLIC ACID(2,5 DIFLUORO 4 METHANESULFINYLPHENYL)AMIDE; 8 (3 PHENYL[1,2,4]OXADIAZOL 5 YL) 1 OXA 2,8 DIAZA SPIRO[4.5]DEC 2 ENE 3 CARBOXYLIC ACID(4 CYANO 2,5 DIFLUOROPHENYL)AMIDE; 9 (2 BROMO 4 METHANESULFONYLPHENYLCARBAMOYL) 3,9 DIAZASPIRO[5.5]UNDECANE 3 CARBOXYLIC ACID TERT BUTYL ESTER; ANTIDIABETIC AGENT; G PROTEIN COUPLED RECEPTOR 199 AGONIST; UNCLASSIFIED DRUG;

ARTICLE; BIOLOGICAL ACTIVITY; COMPUTER MODEL; DRUG ACTIVITY; SYNTHESIS; VIRTUAL REALITY;

CELL LINE; COMBINATORIAL CHEMISTRY TECHNIQUES; DATABASES, FACTUAL; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; ISOXAZOLES; MODELS, MOLECULAR; OXADIAZOLES; RECEPTORS, G-PROTEIN-COUPLED; SPIRO COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP; UREA;

EID: 84871647116     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301549a     Document Type: Article

References (47)

1. Wild, S.; Roglic, G.; Green, A.; Sicree, R.; King, H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 Diabetes Care 2004, 27, 1047-1053 (Pubitemid 38579764)
2. Diabetes Atlas, 2 nd ed.; International Diabetes Federation: Brussels, Belgium, 2003.
3. International Diabetes Federation Diabetes Atlas. The Global Burden. http://www.idf.org/diabetesatlas/5e/the-global-burden (accessed September 2012).
4. Meece, J. Pancreatic islet dysfunction in type 2 diabetes: a rational target for incretin-based therapies Curr. Med. Res. Opin. 2007, 23, 933-944 (Pubitemid 46631496)
5. Overton, H. A.; Babbs, A. J.; Doel, S. M.; Fyfe, M. C.; Gardner, L. S.; Griffin, G.; Jackson, H. C.; Procter, M. J.; Rasamison, C. M.; Tang-Christensen, M.; Widdowson, P. S.; Williams, G. M.; Reynet, C. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents Cell Metab. 2006, 3, 167-175
6. Jones, R. M.; Leonard, J. N.; Buzard, D. J.; Lehmann, J. GPR119 agonists for the treatment of type 2 diabetes Expert Opin. Ther. Pat. 2009, 19, 1339-1359
7. Chu, Z.-L.; Carroll, C.; Chen, R.; Alfonso, J.; Gutierrez, V.; He, H.; Lucmn, A.; Xing, C.; Sebring, K.; Zhou, J.; Wagner, B.; Unett, D.; Jones, R. M.; Behan, D. P.; Leonard, J. N -Oleoyldopamine enhances glucose homeostasis through the activation of GPR119 Mol. Endocrinol. 2010, 24, 161-170
8. Ezzili, C.; Otrubova, K.; Boger, D. L. Fatty acid amide signaling molecules Bioorg. Med. Chem. 2010, 20, 5959-5968
9. Ohishi, T.; Yoshida, S. The therapeutic potential of GPR119 agonists for type 2 diabetes Expert Opin. Invest. Drugs 2012, 21, 321-328
10. Semple, G.; Fioravant, B.; Pereira, G.; Calderon, I.; Uy, J.; Choi, K.; Xiong, Y.; Ren, A.; Morgan, M.; Dave, V.; Thomsen, W.; Unett, D. J.; Xing, C.; Bossie, S.; Carroll, C.; Chu, Z.-L.; Grottick, A. J.; Hauser, E. K.; Leonard, J.; Jones, R. M. Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119 J. Med. Chem. 2008, 51, 5172-5175
11. Wu, Y.; Kuntz, J. D.; Carpenter, A. J.; Fang, J.; Sauls, H. R.; Gomez, D. J.; Ammala, C.; Xu, Y.; Hart, S.; Tadepalli, S. 2,5-Disubstituted pyridines as potent GPR 119 agonists Bioorg. Med. Chem. Lett. 2010, 20, 2577-2581
12. McClure, K. F.; Darout, E.; Guinaraes, C. R. W.; DeNinno, M. P.; Mascitti, V.; Munchhof, M. J.; Robinson, R. P.; Kohrt, J.; Harris, A. R.; Moore, D. E.; Li, B.; Samp, L.; Lefker, B. A.; Futatsugi, K.; Kung, D.; Bonon, P. D.; Cornelius, P.; Wang, R.; Salter, E.; Hornby, S.; Kalgutkar, A. S.; Chen, Y. Activation of the G-protein-coupled receptor 119: a conformation-based hypothesis for understanding agonist response J. Med. Chem. 2011, 54, 1948-1952
13. Semple, G.; Lehmann, J.; Wong, A.; Ren, A.; Bruce, M.; Shin, Y.-J.; Sage, C. R.; Morgan, M.; Chen, W.-C.; Sebring, K.; Chu, Z.-L.; Leonard, J.; A-Shamma, H.; Grottick, A. J; Du, F.; Liang, Y.; Demarest, K.; Jones, R. M. Discovery of a second generation agonist of the orphan G-protein coupled receptor GPR119 with an improved profile Bioorg. Med. Chem. Lett. 2012, 22, 1750-1755
14. Negoro, K.; Yonetoku, Y.; Maruyama, T.; Yoshida, S.; Takeuchi, M.; Ohta, M. Synthesis and structure-activity relationship of 4-amino-2-phenylpyrimidine derivatives as a series of novel GPR119 agonists Bioorg. Med. Chem. 2012, 20, 2369-2375
15. Scott, J. S.; Birch, A. M.; Brocklehurst, K. J.; Broo, A.; Brown, H. S.; Butlin, R. J.; Clarke, D. S.; Davidsson, Ö.; Ertan, A.; Goldberg, K.; Groombridge, S. D.; Hudson, J. A.; Laber, D.; Leach, A. G.; MacFaul, P. A.; McKerrecher, D.; Pickup, A.; Schofield, P.; Svensson, P. H.; Sörme, P.; Teague, J. Use of small-molecule crystal structures to address solubility in a novel series of G protein coupled receptor 119 agonists: optimization of a lead and in vivo evaluation J. Med. Chem. 2012, 55, 5361-5379
16. Lessel, U.; Wellenzohn, B.; Lilienthal, M.; Claussen, H. Searching fragment spaces with feature trees J. Chem. Inf. Model. 2009, 49, 270-279
17. Boehm, M.; Wu, T.-Y.; Claussen, H.; Lemmen, C. Similarity searching and scaffold hopping in synthetically accessible combinatorial chemistry spaces J. Med. Chem. 2008, 51, 2468-2480 (Pubitemid 351628508)
18. Rarey, M.; Dixon, J. S. Feature trees: a new similarity measure based on tree matching J. Comput.-Aided Mol. Des. 1998, 12, 471-490 (Pubitemid 128512818)
19. FTREES, version 2.3.0; Biosolve IT GmbH; St. Augustine, FL, 2010.
20. Rarey, M.; Stahl, M. Similarity searching in large combinatorial chemistry spaces J. Comput.-Aided Mol. Des. 2001, 15, 497-520 (Pubitemid 32680852)
21. Fischer, J. R.; Lessel, U.; Rarey, M. LoFT: Similarity-driven multiobjective focused library design J. Chem. Inf. Model. 2009, 50, 1-21
22. Fischer, J. R.; Lessel, U.; Rarey, M. Improving similarity-driven library design: customized matching and regio-selective feature trees J. Chem. Inf. Model. 2011, 51, 2156-2163
23. Lessel, U.; Wellenzohn, B.; Fischer, J. R.; Rarey, M. Design of combinatorial libraries for the exploration of virtual hits from fragment space searches with LoFT J. Chem. Inf. Model. 2012, 52, 373-379
24. Lauri, G.; Bartlett, P. A. CAVEAT: a program to facilitate the design of organic molecules J. Comput.-Aided Mol. Des. 1994, 8, 51-66
25. Maass, P.; Schulz-Gasch, T.; Stahl, M.; Rarey, M. ReCore: a fast and versatile method for scaffold hopping based on small molecule crystal structure conformations J. Chem. Inf. Model. 2007, 47, 390-399 (Pubitemid 46615943)
26. Molecular Operating Environment (MOE), version 2010.10; Chemical Computing Group Inc. (1010 Sherbooke St. West, Suite No. 910, Montreal, Quebec, Canada, H3A 2R7), 2010.
27. Jones, R. M.; Semple, G.; Xiong, Y.; Shin, Y.-J.; Ren, A. S.; Lehmann, J.; Fioravanti, B.; Bruce, M. A.; Choi, J.; Sun, K. Substituted Aryl and Heteroaryl Derivatives as Modulators of Metabolism and the Prophylaxis and Treatment of Disorders Related Thereto. WO-2005121121, 2005; Arena Pharmaceuticals, Inc.
28. Fevig, J. M.; Wacker, D. A. [6,6] and [6,7]-Bicyclic GPR119 G Protein-Coupled Receptor Agonists. WO-2008137435, 2008; Bristol-Myers Squibb Company.
29. Jones, R. M.; Lehmann, J. Modulators of Metabolism and the Treatment of Disorders Related Thereto. WO-2008005576, 2008; Arena Pharmaceuticals Inc.
30. Bradley, S. E.; Fyfe, M. C. T.; Bertram, L. S.; Gattrell, W.; Jeevaratnam, R. P.; Keily, J.; Procter, M. J.; Rasamison, C. M.; Rushworth, P. J.; Sambrook-Smith, C. P.; Stonehouse, D. F.; Swain, S. A.; Williams, G. M. GPCR Agonists. WO-2007003962, 2007; Prosidion Ltd.
31. ROCS, version 3.1.0; OpenEye Scientific Software, Inc.: Santa Fe, NM, 2010.
32. Corina, version 3.46; Molecular Networks GmbH: Erlangen, Germany, 2008.
33. Omega, version 2.4.3; OpenEye Scientific Software, Inc.: Santa Fe, NM, 2010.
34. Zhu, X.; Huang, D.; Lan, X.; Tang, C.; Zhu, Y.; Han, J.; Huang, W.; Qian, H. The first pharmacophore model for potent G protein-coupled receptor 119 agonist Eur. J. Med. Chem. 2011, 46, 2901-2907
35. Valeur, E.; Bradley, M. Amide bond formation: beyond the myth of coupling reagents Chem. Soc. Rev. 2009, 38, 606-631
36. Jones, R. M.; Semple, G.; Fioravanti, B.; Pereira, G.; Calderon, I.; Uy, J.; Duvvuri, K.; Choi, J. S. K.; Xiong, Y.; Dave, V. 1,2,3-Trisubstituted Aryl and Heteroaryl Derivatives as Modulators of Metabolism and the Prophylaxis and Treatment of Disorders Related Thereto Such as Diabetes and Hyperglycemia. WO-2004065380, 2004; Arena Pharmaceuticals Inc.
37. Buzard, D. J.; Lehmann, J.; Han, S.; Jones, R. M. GPR119 agonists 2009-2011 Pharm. Pat. Anal. 2012, 1, 285-299
38. Bertram, L. S.; Fyfe, M. C. T.; Jeevaratnam, R. P.; Keily, J.; Krulle, T. M.; Rasamison, C. M.; Sambrook-Smith, C. P.; Swain, S. A. Piperidinyl GPCR Agonists. WO-2010004343, 2010; Prosidion Limited.
39. Wood, H. B.; Szewczyk, J. W.; Huang, Y.; Adams, A. D. Substituted Cyclopropyl Compounds, Compositions Containing Such Compounds and Methods of Treatment. WO-2009129036, 2009; Merck & Co. Inc.
40. Wood, H. B.; Adams, A. D.; Szewczyk, J. W.; Zhang, Y.; Yang, M. Substituted Cyclopropyl Compounds, Compositions Containing Such Compounds and Methods of Treatment. WO-2011019538, 2011; Merck Sharp & Dohme Corp.
41. Birch, A. M; Broo, D. A.; Butlin, R. J.; Clarke, D. S.; Davidsson, O. P.; De La Motte, H.; Johansson, K. E.; Leach, A.; Macfaul, P. A.; O'Donnell, C. J.; Scott, J. S.; Whittamore, P. R. O. 4-(Pyrimidin-2-yl)-piperazine and 4-(Pyrimidin-2-yl)-piperidine Derivatives as GPR119 Modulators. WO-2011030139, 2011; AstraZeneca UK Limited.
42. Bertram, L. S.; Fyfe, M. C. T. Piperidinyl GPCR Agonists. WO-2010004345, 2010; Prosidion Limited.
43. Carpenter, A. J.; Fang, J.; Peckham, G. Chemical Compounds and Uses. WO-2010014593, 2010; Smithkline Beecham Corporation.
44. Barba, O.; Bell, J. C.; Dupree, T. B.; Fry, P. T.; Bertram, L. S.; Fyfe, M. C. T.; Gattrell, W.; Jeevaratnam, R. P.; Keily, J.; Krulle, T. M.; Mcdonald, R. W.; Morgan, T.; Rasamison, C. M.; Schofield, K. L.; Stewart, A. J. W.; Swain, S. A.; Withall, D. M. Cycloamino Derivatives as GPR119 Agonists. WO-2011147951, 2011; Prosidion Ltd.
45. MDL ISIS/Draw, version 2.5 SR 3; MDL Information Systems, Inc.: San Leandro, CA, 1990-2003.
46. Pipeline Pilot, version 8.0.1; Accelrys Software Inc: San Diego, CA, 2010.
47. Miyazaki, J.; Araki, K.; Yamato, E.; Ikegami, H.; Asano, T.; Shibasaki, Y.; Oka, Y.; Yamamura, K. Establishment of a pancreatic beta cell line that retains glucose-inducible insulin secretion: special reference to expression of glucose transporter isoforms Endocrinology 1990, 127, 126-132 (Pubitemid 20228111)